Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials? 

Question Title

* 2. What is your specialty?

Question Title

* 3. How confident are you in the management of patients with ALL in your practice?

Question Title

* 4. Incorporation of blinatumomab into the treatment strategy for front-line therapy of high risk-disease in adult patients with Philadelphia chromosome negative ALL and in children and adolescents/young adults with low-risk, first relapse ALL demonstrated which of the following?

Question Title

* 5. WA is a 12-year-old girl diagnosed with B-cell ALL 3 years ago with a first isolated marrow relapse after completing maintenance therapy. She is MRD negative after reinduction on AALL1331. 

Which of the following should be incorporated into management of WA?

Question Title

* 6. Compared with chemotherapy as post-reinduction therapy in low-risk, first relapse of B-cell ALL in children and adolescents/young adults, which of the following best reflects outcomes associated with the incorporation of blinatumomab?

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

( Privacy & Cookie Notice

T